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ABSTRACT
Background Human telomerase reverse transcriptase
(hTERT) is frequently classified as a ‘universal’ tumor
associated antigen due to its expression in a vast number
of cancers. We evaluated plasmid DNA-encoded hTERT as
an immunotherapy across nine cancer types.
Methods A phase 1 clinical trial was conducted in adult
patients with no evidence of disease following definitive
surgery and standard therapy, who were at high risk of
relapse. Plasmid DNA encoding one of two hTERT variants
(INO-1400 or INO-1401) with or without plasmid DNA
encoding interleukin 12 (IL-12) (INO-9012) was delivered
intramuscularly concurrent with the application of the
CELLECTRA constant-current electroporation device 4
times across 12 weeks. Safety assessments and immune
monitoring against native (germline, non-mutated, non-
plasmid matched) hTERT antigen were performed. The
largest cohort of patients enrolled had pancreatic cancer,
allowing for additional targeted assessments for this tumor
type.
Results Of the 93 enrolled patients who received at least
one dose, 88 had at least one adverse event; the majority
were grade 1 or 2, related to injection site. At 18 months,
54.8% (51/93) patients were disease-free, with median
disease-free survival (DFS) not reached by end of study.
For patients with pancreatic cancer, the median DFS was 9
months, with 41.4% of these patients remaining disease-
free at 18 months. hTERT immunotherapy induced a de
novo cellular immune response or enhanced pre-existing
cellular responses to native hTERT in 96% (88/92) of
patients with various cancer types. Treatment with INO1400/INO-1401±INO-9012 drove hTERT-specific IFN-γ
production, generated hTERT-specific CD4+ and CD8+
T cells expressing the activation marker CD38, and
induced hTERT-specific activated CD8 +CTLs as defined
by cells expressing perforin and granzymes. The addition
of plasmid IL-12 adjuvant elicited higher magnitudes of
cellular responses including IFN-γ production, activated

CD4+ and CD8+ T cells, and activated CD8+CTLs. In
a subset analysis of pancreatic cancer patients, the
presence of immunotherapy-induced activated CD8+ T
cells expressing PD-1, granzymes and perforin correlated
with survival.
Conclusions Plasmid DNA-encoded hTERT/IL-12 DNA
immunotherapy was well-tolerated, immune responses
were noted across all tumor types, and a specific
CD8+ phenotype increased by the immunotherapy was
significantly correlated with survival in patients with
pancreatic cancer.

INTRODUCTION
The telomerase complex is critical for maintaining telomere length at chromosome ends
during the semiconservative DNA replication
and is expressed mainly in embryonic cells.1–3
Reactivation of telomerase is a primary mechanism of cell immortalization leading to
cancer.4–6 Human telomerase reverse transcriptase (hTERT), the catalytic subunit of
the telomerase complex, is highly expressed
in more than 85% of human tumors of diverse
origin.6 7 In contrast, hTERT is not expressed
in somatic cells, aside from low expression
in a few cell types with high self-
renewal
capacity.8–11 Telomerase has additional functions beyond maintaining telomere ends that
contribute to its oncogenic properties, which
include promoting cell proliferation, resistance to apoptosis, epithelial to mesenchymal
transition, transcriptional regulation and
metabolic reprogramming.12 13 Furthermore,
hTERT expression has been demonstrated in
cells from all stages of cancer development,
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further impact host immunity uniquely. The INO-1400/
INO-1401 plasmids encode for full length hTERT, which
is processed endogenously, resulting in presentation
of peptides across multiple HLA alleles. Importantly,
this hTERT DNA vaccine was shown to induce strong
immunological responses in both mice and non-human
primates.44
Here, we explore the safety and immunogenicity
of plasmids encoding modified hTERT (INO-1400/
INO-1401) alone or in combination with interleukin 12
(IL-12) plasmid (INO-9012) in patients with various solid
tumors (breast, lung, pancreatic, head and neck, ovarian,
colorectal, gastric, esophageal or hepatocellular) who are
at a high risk of relapse post definitive surgery and standard adjuvant therapy.

MATERIALS AND METHODS
Study population
Patients, at least 18 years old, with one of nine specific
solid tumors: breast carcinoma (stage II with axillary
node-positive disease, stage III or stage IV following metastatectomy), non-small cell lung cancer (stage IB, II, IIIA;
stage IIIB or stage IV following metastatectomy), pancreatic ductal adenocarcinoma (stage I, II, III; stage IV
following metastatectomy), head and neck squamous cell
carcinoma (AJCC 7 stage III; stage IV following metastatectomy), ovarian carcinoma (stage III; stage IV following
metastatectomy), colorectal adenocarcinoma (stage III;
stage IV following metastatectomy), gastric or esophageal
carcinoma (Stage IIB, III), or hepatocellular carcinoma
(any stage, ineligible for and not post-liver transplantation; Child-Pugh class A required) who were at high risk
of relapse, had been treated with curative intent, and
had no evidence of disease (NED) following front-line
therapy were enrolled. Therapy was completed no fewer
than 4 weeks, and no later than 25 weeks, before first dose
of study drug(s). Patients had an Eastern Cooperative
Oncology Group performance status of 0–1, adequate
organ function and no higher than National Cancer Institute Common Terminology Criteria for Adverse Events
(CTCAE; version 4.03) grade 1 or 2 laboratory parameters at screening. Patients were excluded if they received
based
treatment with any hTERT targeted or IL-12-
therapy in the past or any immune modulators within
the past 3 years, had metastasis in the brain or central
nervous system, had any malignant condition requiring
active treatment, any clinically significant autoimmune
disease or were chronically immunosuppressed. Written
informed consent was obtained from each patient prior
to performing any assessments.
Immunotherapy and delivery using CELLECTRA device
INO-1400 and INO-1401 are synthetic DNA plasmids
encoding for a modified human telomerase protein.
INO-9012 consists of a DNA plasmid encoding for
synthetic human IL-12 (p35 and p40 subunits). All
constructs were designed using proprietary technology
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including cancer stem cells.5 6 14–16 Therefore, therapies
that target hTERT have the potential to abrogate cancer
stem cells as well as cells in all other stages of cancer
development. Because hTERT is expressed in such a vast
number of cancers and cancer cell stages, it has been classified as a ‘universal’ tumor-associated antigen.17 18
Several studies have shown that cancer cells process and
present epitopes from hTERT on Major Histocompatibility Complex (MHC).19–24 In addition, CD8+ and CD4+T
cells specific for hTERT can be detected in the blood
of both healthy individuals and cancer patients.25–28
Telomerase-
specific CD8 +T cells have been found in
patients with cancers including prostate, breast, lung,
gastric, and colorectal, as well as hepatocellular carcinoma, chronic myeloid leukemia and non-
Hodgkin’s
lymphoma.24–26 29–32 Telomerase-specific CD4 +T cells are
also found in patients with cancers and associate with
overall survival in non-small cell lung cancer, renal cell
carcinoma, and anal squamous cell carcinoma.27 33 These
studies demonstrate that although telomerase is a self-
antigen, some hTERT-specific T lymphocytes are able to
escape thymic deletion.
To date, a number of clinical trials have been performed
using immunotherapies to target hTERT, including vaccination.9 24 The trials competed thus far have shown that
targeting hTERT with vaccines is safe and can induce
immunological responses in 50%–100% of vaccinated
patients.18 34 35 Several trials have also demonstrated
a clear correlation between vaccine-
induced immune
responses and clinical response.36–39 Vaccines tested in
clinical trials thus far include mainly peptide vaccines and
dendritic cell vaccines.9 24 DNA vaccines targeting hTERT
are less common but have also been tested.40 41 In a phase
I clinical trial using INVAC-1, a modified full-
length
hTERT vaccine, hTERT-
specific CD8+ and CD4+T cell
responses were detected in 25% and 63% of patients,
respectively, and disease stabilization was observed in
58% of patients.41 However, the length of stable disease
was only 2.7 months, which is shorter than previous
studies using hTERT peptide or dendritic cell vaccines.36
Taken together, the results of clinical trials demonstrate
that while hTERT-based vaccination can induce immune
responses in patients, these immune responses to date
have not generally been enough to control tumor growth
or disease progression in advanced cancer patients.24
Improvements in DNA vaccines can be accomplished
using modifications to increase processing and immunogenicity, which may lead to increased vaccine efficacy, and
be engineered to help evade tolerance.42 The INO-1400
and INO-1401 plasmids encode a modified version of
full-length hTERT that are RNA and codon optimized
and both contain a highly efficient leader sequence.
The INO-1400 plasmid includes two point mutations in
the hTERT sequence to aid in breaking tolerance43 44
and remains over 99% homologous to the native hTERT
sequence, while the INO-1401 plasmid encodes a
further modified hTERT sequence with approximately
95% similarity to the native hTERT protein, which may
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Study design
This phase 1, multicenter, open-
label, dose-
escalation
study was performed in adults with NED following definitive surgery and standard adjuvant therapy, who are at
high risk of relapse. Following informed consent, each
patient was enrolled into one of 10 treatment arms
(online supplemental table 1) for a total of nine patients
per treatment arm: Arm 1: 2 mg INO-1400, Arm 2: 8 mg
INO-1400, Arm 3: 2 mg INO-1400 +0.5 mg INO-9012,
Arm 4: 2 mg INO-1400 +2 mg INO-9012, Arm 5: 8 mg
INO-1400 +0.5 mg INO-9012, Arm 6: 8 mg INO-1400 +mg
INO-9012, Arm 7: 2 mg INO-1401, Arm 8: 8 mg INO-1401,
Arm 9: 8 mg INO-1401 +0.5 mg INO-9012, Arm 10: 8 mg
INO-1401 +2 mg INO-9012. Patients received the first of
four doses of either INO-1400 or INO-1401 with or without
INO-9012 on day 0, followed by three additional doses
each given 4 weeks apart. Blood collection for immunological analyses occurred at weeks 0, 2, 6, 10 and 14, and
every 12 weeks thereafter. Radiological disease assessment
was requested at screening and every 12 weeks.
A modified ‘3+3’ design was used to assess safety and
tolerability in up to the first 6 patients in each arm regardless of tumor type. Patients were then enrolled to the next
treatment if there was 0/3 or 1/6 dose limiting toxicities
(DLTs) in the arm. Arms were opened sequentially once
each patient had been assessed for a minimum of 6 weeks
followed by a safety review of all available data. Enrollment to Arm 7, the first dosing arm of INO-1401, was not
contingent on an additional safety review of INO-1400.
DLTs were defined as related CTCAE ≥grade 3 injection site erythema, swelling or induration after study
treatment; pain or tenderness at the injection site that
required overnight hospitalization despite proper use of
non-narcotic analgesics; ≥grade 3 headache in patients
who did not have a history of recurrent headaches; or
≥grade 3 laboratory abnormalities.
The primary objective was to evaluate the safety and
tolerability of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered IM, followed by EP. The
secondary objectives were to determine the humoral and
cellular immune responses and the exploratory objectives
were to evaluate disease-free survival (DFS) and overall
survival (OS).
 linicalTrials.gov with the
The study was registered on C
identifier NCT02960594.
Safety assessments
Local and systemic adverse events (AEs), vital signs,
targeted physical assessments, and the development of

laboratory abnormalities were monitored from the date
of informed consent through the last follow-up visit. In
particular, injection site reactions, including local skin
erythema, induration, pain and tenderness were assessed
via a participant reminder card on the day of each treatment and for three consecutive days post-
treatment.
Patients were queried at each visit for new AEs or disease
and use of concomitant medications. All events were
graded in accordance with CTCAE V.4.03 and all injection site reactions were measured in accordance with
the U.S. Food and Drug Administration (FDA) Guidance for Industry- Toxicity Grading Scale for Health
Adult and Adolescent Volunteers Enrolled in Preventive
Vaccine Clinical Trials (September 2007) and coded with
MedDRA V.21.0.
Further enrolment and treatment were to be stopped
if one third or more patients experienced a DLT; unexpected grade 4 toxicity; potentially life-threatening AE
or death assessed as related to study treatment; three or
more patients experienced the same related grade 3 or 4
AE; or any report of grade 3 anaphylaxis.
Women of childbearing potential completed a β-HCG
test at screening and within 3 days prior to each dose.
Laboratory parameters including hematology, coagulation, serum chemistry (including liver function) and
creatine phosphokinase were monitored throughout the
study and assessed locally at the center.
Sample collection
Whole blood was collected in ACD-A tubes and peripheral blood mononuclear cells (PBMCs) were isolated,
followed by cryopreservation. For analysis, PBMCs were
thawed, recovered overnight in cell culture medium,
spun, washed and resuspended the following day for
cellular immune analyses in batches.
Interferon gamma ELISpot
A standard ELISpot assay was performed (MabTech,
OH). Briefly, PBMCs were stimulated with native hTERT
peptides or media and DMSO (negative control) at the
same concentration (2 µg/mL) for 18–24 hours. The
peptides were 15–amino acids in length, overlapping by
eight amino acids, and encompass the entire native hTERT
sequence. The peptides were split up into four pools
such that each pool includes approximately a quarter of
the peptides in a sequential format. The hTERT-specific
values graphed are the sum of the background subtracted
four hTERT peptide pool stimulated wells at baseline
(pre) and the study week with the highest value (peak).
Lytic granule loading
1×106 PBMCs were stimulated 5 days with peptides corresponding to hTERT pooled at a concentration of 2 µg/
mL, while an irrelevant peptide was used as a negative
control (OVA) and concanavalin A was used as a positive
control (Sigma-Aldrich). No co-stimulatory antibodies or
cytokines were added to cell cultures at any point. After
5 days, cells wee stained for CD3, CD4, CD14, CD16,

Vonderheide RH, et al. J Immunother Cancer 2021;9:e003019. doi:10.1136/jitc-2021-003019

3

J Immunother Cancer: first published as 10.1136/jitc-2021-003019 on 6 July 2021. Downloaded from http://jitc.bmj.com/ on July 22, 2021 by guest. Protected by copyright.

(Inovio Pharmaceuticals, Inc.). The CELLECTRA 2000
adaptive constant current electroporation device (EP;
Inovio Pharmaceuticals) delivers three 52 ms controlled
electric pulses, spaced in 1 s intervals, through a sterile,
disposable array to the injection site. INO-1400/1401 with
or without INO-9012 was formulated in sterile water for
injection and delivered intramuscularly (IM) in a 1 mL
volume followed immediately by EP.

Open access

Statistical methods
The study was designed to be analyzed descriptively and
did not include any formal statistical hypothesis. Any
patient who received at least one treatment dose and had
data available post first dose was included in the primary
and safety analyses. Patients were allocated to the modified intention-
to-
treat (mITT) and per-
protocol (PP)
populations for secondary cellular and humoral immunogenicity and exploratory Kaplan-
Meier analyses of
DFS efficacy analyses. The mITT population included all
patients who received at least one dose of study treatment.
For the primary objective, the percentage of patients with
AEs and DLTs was summarized along with corresponding
exact 95% Clopper-Pearson CIs for each treatment arm
and overall. Continuous outcomes such as laboratory
observations and vital signs were summarized using the
mean/median, SD, range and 95% CI. Binary outcomes
such as number of relapsed patients were summarized
Pearson 95% CI.
using proportion and exact Clopper-
Time to event outcomes were analyzed using the Kaplan-
Meier method on all treatment cohorts combined as well
as separately by indication. The Kaplan-Meier statistics
included the number of relapses and deaths, number of
censored patients, Kaplan-Meier estimates at 3, 6, 12 and
18 months from the time of first dose (day 0), and the
median time to DFS from time of first dose (day 0) with
95% CI based on the log-log transformation.
Wilcoxon-
Mann-
Whitney rank sum tests (between
cohorts) or Wilcoxon signed-rank tests (within cohorts)
were used to assess the significance of immunogenicity
analyses due to the non-normality of these types of data.
Because these analyses were intended to be hypothesis-
generating for future studies, p values were not corrected
for multiplicity and therefore do not account for type I
errors.
All statistical analyses were conducted in SAS V.9.4 and
Prism V.8.4.3.

RESULTS
Clinical characteristics
A total of 93 patients with one of nine solid tumor types
were enrolled between February 6 2015 and January 26
2018 (table 1). The largest cohort of patients had pancreatic cancer (34 of 93; 37%), followed by colorectal cancer
(18 of 93; 19%) and non-small cell lung cancer (14 of
93; 15%) (online supplemental table 2). The median
4

Table 1

Patientdemographics (mITT population)

Variable
Age (years)

Gender
Race

Statistics/response
category

Total (N=93)

Mean
Median

56.41
58.00

Min, Max

28.0, 76.0

Female

61 (65.6%)

Male

32 (34.4%)

American Indian or Alaskan 0 (0.0%)
Native
Asian

Cancer type

0 (0.0%)

Black or African American

6 (6.5%)

Native Hawaiian or other
Pacific lslander

0 (0.0%)

White

84 (90.3%)

Other

3 (3.2%)

Breast carcinoma

10 (10.8%)

Squamous non-small cell
lung cancer

14 (15.1%)

Pancreatic carcinoma

34 (36.6%)

Head and neck squamous
cell carcinoma

3 (3.2%)

Ovarian cancer

9 (9.7%)

Colorectal cancer
18 (19.4%)
Gastric cancer

0 (0.0%)

Esophageal caucer
Hepatocellular carcinoma

3 (3.2%)
2 (2.2%)

age was 58 years (range 28 to 76 years). Sixty-six percent
of patients were female, 90% were white, and 93% were
non-Hispanic/Latino. All 93 patients received at least one
dose PP.
Safety
Of 93 patients who received at least one dose, 88 (94.6%)
had at least one AE with 77.4% of these being grade 1 or
2. Sixteen patients (17.2%) reported at least one grade
3 event, and one patient had a grade 4 event of sepsis
(online supplemental table 3); no grade 5 events were
reported. Of the AEs reported across all arms, injection
site reactions (grades 1 and 2) were reported most often,
with injection site pain (76 patients; 81.7%), injection
site swelling (18; 19.4%), injection site erythema (18;
19.4%), and injection site bruising (11; 11.8%) reported.
Fatigue was reported in 19 (20.4%) patients, abdominal
pain in 10 (10.8%), diarrhea in 10 (10.8%), and pain in
extremity in 10 (10.8%). There were 19 SAEs reported
in 11 (11.8%) patients, only two grade 3 events (breast
cellulitis and abdominal pain) were considered treatment related. There was one treatment-related AE (rash,
maculopapular) that was considered dose-limiting and
led to study drug being permanently discontinued in this
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CD137, granulysin, CD19, CD38, CD8, granzyme B (BD
Biosciences), granzyme A (ThermoFisher), Programmed
Cell Death-1 (PD1), perforin, and CD69 (BioLegend).
Staining for extracellular markers (CD4, CD8, CD137,
CD69, CD38, PD-1) occurred first, followed by permeabilization to stain for the remaining markers. The frequency
of hTERT-specific responses per output are calculated by
subtracting the background frequency in the negative
control wells. Acquired data were analyzed using the
FlowJo software version X.0.7 or later (Tree Star).

Open access

patient. (online supplemental table 3) lists grade 3 and 4
AEs by System Organ Class and Preferred Term reported,
of any relationship.
Survival and disease-free analysis
Online supplemental figure 1 shows Kaplan-Meier analysis of DFS across all treatment arms in the mITT population (N=93). At 18 months, 54.8% of all patients were
disease-free, with median DFS not reached by end of the
study. For patients with pancreatic cancer, the median
DFS was 9 months with 95% CI (4.5 to not available),
with 41.4% of these patients disease-free at 18 months
(figure 1). Online supplemental figure 2 shows time from
diagnosis to first dose (day 0) of study treatment, and
time on study from day 0 by tumor type.

Figure 2 IFN-γ ELISpot responses broken out by hTERT dose, IL-12 dose, and tumor type. (A, C, E) Open symbols represent
individual patients, the box extends from the 25 th to the 75 th percentile, line inside the box is a the median, and the
whiskers extend from the minimum to maximum values. Wilcoxon signs rank test was used to assess significance between
the magnitude of IFN-g in patients before (PRE) and after (POST) immunotherapy. The number of patients in each group is
displayed below the graph, N. (B, D) The increase over baseline is shown for each group. Wilcoxon ranked sum test was used
to assess significance of the increase over baseline between treatment groups. The number of patients, means, medians and
ranges of the delta magnitudes for each treatment group are shown. IFN-γ ELISpot responses broken out by hTERT dose, IL-12
dose, and cancer type. hTERT, human telomerase reverse transcriptase; IFN-γ, interferon-γ; IL-12, interleukin 12.
Vonderheide RH, et al. J Immunother Cancer 2021;9:e003019. doi:10.1136/jitc-2021-003019
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Figure 1 Kaplan-Meier analysis of disease-free survival
in pancreatic carcinoma Patients (mITT population, N=34).
mITT, modified intention-to-treat.

INO-1400/1401 induces hTERT-specific interferon gamma
production from T cells
IFN-γ ELISpot was used to assess levels of cellular reactivity
to the endogenous form of hTERT before, during and
following completion of immunotherapy in all treated
patients with available sample (n=92). The peak response
(defined as the highest magnitude observed above the
day of treatment initiation) was identified for each individual and graphed together with the predose time point
value for each treatment arm. Magnitudes of hTERT-
specific IFN-γ secreting cells significantly increased in 9
out of 10 arms (online supplemental figure 3A). Immune
responses against hTERT antigen were similar when
comparing the increases over baseline for INO-1400 and
INO-1401 immunotherapies (online supplemental figure
3B) and cohorts were therefore combined for further
analysis. The impact of hTERT dose as well as the inclusion and dose of IL-12 on the immune response following
immunotherapy was also explored. Patients were also
grouped by tumor type to assess the response to immunotherapy across various cancers.
Patients given a low (2 mg) or high (8 mg) dose of hTERT
immunotherapy had similar significant increases in the
number of hTERT-specific IFN-γ secreting cells from pre-
dose to peak post-dose time points, p=0.003 and p=0.015
for low and high-dose groups, respectively (figure 2A,
top row). The median spot-forming unit (SFU, cells per
million PBMCs) values post treatment were 20 and 14.5
with a maximum response of 48.9 and 88.9, respectively.
dose and high-
dose cohorts that received IL-12
Low-
also had significant increases in the number of hTERT-
specific IFN-γ secreting cells (p<0.001) from predose

Open access

INO-1400/1401 induces hTERT-specific activated CD4+ and
CD8+T cells
To characterize the function of the immune response
elicited by the immunotherapy, hTERT-specific responses
were assayed on CD4+ and CD8+T cells using flow
cytometry based on percent expression of the activation
marker CD38. The change in expression of CD38 on CD4
+T cells was similar post treatment regardless of dose
(figure 3A). Specifically, 29.6% of patients receiving the
2.0 mg dose of immunotherapy exhibited an increase in
hTERT-specific CD4 +T cells after treatment compared
with 20% of patients receiving the 8.0 mg dose. For both
6

hTERT doses, overall magnitudes of CD4 +CD38+T cells
increased after treatment with a difference in the means
of 0.06% and 0.1% in the 2 mg and 8 mg dose groups,
respectively (figure 3A, left panel). When assessing CD8
+T cells expressing CD38, the frequency of patients
exhibiting hTERT-
specific responses was again similar
with 25.9% in the 2.0 mg group and 20.6% in the 8.0 mg
group displaying increases in frequencies after treatment.
However, the overall magnitude of response was higher
in the 2.0 mg group showing an increase in the difference
of the means of 0.37% after treatment, while the 8.0 mg
group showed a decrease in the difference of the means
after treatment of 0.19% (figure 3A, right panel).
We additionally profiled immune responses to
INO-1400/1401 as a function of IL-12 plasmid dose, which
was tested at 0.5 mg (low) and 2.0 mg (high) (figure 3B).
Of the patients who did not receive any IL-12 adjuvant,
15.4% had an increase in the frequency of hTERT-specific
CD4 +T cells following treatment. In the patients who
received the IL-12 adjuvant, 25.0% of the low-dose and
35.0% of the high-
dose recipients had an increase in
the frequency of activated CD4 +T cell frequencies after
treatment. There was in increase in the difference of
the means postdose versus predose of 0.12% in the low-
dose and 0.20% in the high-dose IL-12 treatment groups.
Similar trends were observed in the CD8 +T cell compartment, for which a numerically higher number of patients
had increases in activated hTERT-
specific cells in the
IL-12 treated groups. Specifically, 33.3% of the low-dose
IL-12% and 31.6% of the high-dose IL-12 recipients had
increases in the frequency of these cells compared with
11.1% of patients who did not receive IL-12. The largest
mean difference of 0.37% was observed in the high-dose
IL-12 group, followed by 0.03% in the low-dose IL-12
group. The postdose mean value in the no IL-12 group
decreased by 0.15% compared with the predose mean
value.
Last, we looked at the ability of INO-1400/1401
to induce CD4+ and CD8+T cell activation based on
disease condition. To that end, we considered patients
based on the six tumor types, as noted above in
(figure 3C). Colorectal, lung and pancreatic cancer
diagnoses had the highest patient numbers for analysis with 15, 11 and 19, respectively. Observation of
the CD4 +T cell compartment revealed that patients
with breast, colorectal, ovarian and pancreatic tumors
exhibited hTERT-specific activation as evidenced by
CD38 upregulation (figure 3C left panel). In particular, the patients with colorectal and pancreatic cancer
saw the highest frequency of increase over predose
values with 26.7% and 36.8% of patients responding,
respectively. In the CD8 +T cell compartment, similar
trends were noted, that is, breast, colorectal and
specific activapancreatic patients exhibited hTERT-
tion as evidenced by CD38 upregulation (figure 3C
right panel). Similar to CD4 +T cell activation, 33.3%
of patients with colorectal cancer had an increase in
activated CD8 +T cells postimmunotherapy, although
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to peak postdose time points (figure 2A, bottom row).
Moreover, the inclusion of IL-12 significantly improved
immunotherapy induced responses, as defined by the
change in hTERT-specific SFU from predose to the peak
postdose response time point in the low-
dose group
(p=0.028, figure 2B), and increased the median change
in SFU 2.5-fold with a maximum magnitude of 617.8 SFU.
Magnitudes in the high-dose cohort that received IL-12
had higher SFU values than the high-dose cohort without
IL-12 (peak response of 338.9 vs 67.8, respectively), as
well as a 2.8-fold higher median change from baseline
that did not reach significance.
The effect of the dose of the cytokine adjuvant,
IL-12, was also explored, irrespective of antigen dose
(figure 2C). Patients who received no IL-12, a low dose
of IL-12 (0.5 mg), or a high dose of IL-12 (2.0 mg) had
significant increases in the number of hTERT-
specific
IFN-γ secreting cells (p<0.001 in each case) from predose
to peak postdose time points (figure 2C). Both doses of
IL-12 examined resulted in numerically higher hTERT-
specific SFUs above predose compared with the arms
without IL-12 (figure 2D), but the delta magnitudes were
not significantly different from one another (figure 2D).
The number of patients with samples for immunology
testing were as follows pancreatic (n=34), colorectal
(n=18), lung (n=13), ovarian (n=9), breast (n=10), and
‘other’ (n=8). The ‘other’ subgroup consisted of patients
with gastric (n=1), head and neck (n=3), esophageal
(n=2), and hepatocellular (n=2) cancer types. When
grouped together by cancer types, significant increases
in IFN-γ secreting cells following immunotherapy were
observed in pancreatic (p<0.001), lung (p<0.001), and
ovarian (p=0.012) cancer patients (figure 2E). Patients
with colorectal and breast cancer had numerical increases
as well but not statistically significant (p=0.062 and
p=0.088, respectively).
To determine whether patients with pre-
existing
hTERT-specific IFN-γ secreting cells responded more
favorably to immunotherapy, patients were divided into
two groups based on the presence or absence of hTERT-
specific IFN-γ secreting cells at baseline. The increase
over baseline following immunotherapy was not statistically different between the two groups, although the
mean was numerically higher in the group that had pre-
existing responses (online supplemental figure 3C).
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the magnitude of increase over predose values was low
(difference in means of 0.07%) In addition, 31.6% of
patients with pancreatic cancer exhibited an increase
over predose frequencies, with a difference in means
of 0.67%.
CD8+ T cells activated by INO-1400/1401 exhibit lytic
potential
To further characterize the function of the immune
response elicited by the immunotherapy, hTERT-
specific responses were assayed using a lytic granule
loading (LGL) assay that examines the activation status
and lytic potential of CD8 +T cells. Example flow plots
of live CD3 +CD8+T cells expressing the activation

marker CD38 and lytic proteins perforin, granzyme A
and granzyme B are shown in figure 4A. The low-dose
hTERT immunotherapy arms had numerical increases
after treatment in the means of hTERT-specific activated CD38 +CD8+T cells with lytic potential, coexpressing granzyme A, granzyme B, and perforin
(0.17%, figure 4B, left panel). In contrast the high-
dose hTERT arms had a trend toward higher frequencies that were not boosted following immunotherapy
and resulted in numerical decreases in the difference
of the means (0.18). However, a similar number of
patients had an increase in activated CD8 +T cells
with lytic potential- 22.2% (6/27) and 23.5% (8/34)
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Figure 3 Activated CD4+ (left column) or CD8+ (right column) T cells broken out by hTERT dose, IL-12 dose and cancer type.
(A–C) Open symbols represent individual patients, the mean is represented with ‘+’, the box extends from the 25 th to the 75
th percentile, line inside the box is a the median, and the whiskers extend from the minimum to maximum values. Wilcoxon
signs RANK test was used to assess significance between the magnitude of IFN-g in patients before (PRE) and after (POST)
immunotherapy. The number and percent of patients in each group that had an increase, decrease or no change from baseline
is displayed below each graph. hTERT, human telomerase reverse transcriptase; IFN-g, interferon-γ; IL-12, interleukin 12.
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Figure 4 Activated CD8 +T cells with lytic potential broken out by hTERT dose, IL-12 dose and cancer type. (A) Representative
dot plot showing CD8 +T cells expressing the activation marker CD38 and lytic granules—perforin, granzyme A and granzyme
B. (B, C) Open symbols represent individual patients, the mean is represented with ‘+’, the box extends from 25 th to 75 th
percentile, line inside the box is a the median, and the whiskers extend from the minimum to maximum values. Wilcoxon
signs rank test was used to assess significance between the magnitude of IFN-g in patients before (PRE) and after (POST)
immunotherapy. The number and per cent of patients in each group that had an increase, decrease or no change from baseline
is displayed below each graph. hTERT, human telomerase reverse transcriptase; IFN, interferon; IL-12, interleukin.

Open access

INO-1400/1401 induced hTERT-specific CTLs are associated
with DFS in patients with pancreatic cancer
Given the relatively high number of patients on study
with pancreatic cancer and an immune profile suggesting
the induction of both hTERT-specific CD4 T cells and
CTLs (figures 3C, 4C, respectively), we analyzed immune
responses induced by INO-1400/1401 relative to overall
survival. To perform these analyses, a subset of pancreatic cancer patients (n=23) were followed prospectively
during the conduct of the study and following its completion (figure 5A). Overall, 74% (n=17) of patients were
alive at the last date of long-term follow-up (mean 428
days, range 1–1062 days). Of the 17 surviving patients,
(10/17, 59%) exhibited NED at last contact (online
supplemental table 4). The amount of time between the
initial diagnosis of local disease and study day 0, as well as
the time between study day 0 and last contact, is shown in
figure 5A. The majority of confirmed deaths (5/6, 83%)
were recorded prior to 3.5 years from diagnosis. The
longest noted survival for the final deceased patient was
5.1 years (1876 days from diagnosisin patient 51045) while
the longest tracked survival for a patient not yet deceased
is 7.8 years (2844 days from diagnosis in patient 51034).
As the upregulation of CD38 on both CD4+ and CD8+T
cells specific for hTERT was observed following immunotherapy, we explored the clinical relevance of this marker
in relation to survival benefit for these patients. An

in-depth immune analysis including the additional activation markers CD69 and PD1 (figure 5B) was performed on
pancreatic cancer patients with available sample (n=12; 8
alive, 4 deceased). The expression of CD38 continued to
be an important marker of immune activation relative to
survival in this analysis. In particular, the majority of pancreatic cancer patients who were alive at the last follow-up visit
exhibited an increase post immunotherapy in the frequency
of hTERT-
specific CTLs expressing granzyme B and
perforin within the population of CD8 +T cells expressing
CD38, CD69 and PD1 (figure 5C). The mean frequency
of these cells was 0.58% at baseline and 7.29% following
immunotherapy in the group of surviving patients representing an overall absolute increase of 6.71%, or a >12-fold
increase from study start. Conversely, the patients who were
deceased as of last contact exhibited a marked reduction
in the frequency of these cells from 2.38% to 1.13% (absolute difference of −1.25%, a 0.47-fold change) (figure 5C).
Overall the increase in CTLs expressing granzyme B and
perforin within the population of CD8 +T cells expressing
CD38, CD69, and PD1 above baseline in surviving patients
(mean, 6.71%; median, 4.13%) was higher than the change
in deceased patients (mean, −1.15%; median, −0.91%)
(p=0.028) (figure 5D). Taken together, these findings
demonstrate that INO-1400/INO-1401±INO-9012 induces
hTERT-specific T cells that correlate with survival in some
patients with cancer.
CONCLUSION
In this study, we used a DNA plasmid encoding a full-length
optimized hTERT sequence (INO-1400 or INO-1401) with
or without IL-12 DNA plasmid (INO-9012) to generate
cellular responses to hTERT in high risk solid tumor patients
with NED after local resection and standard neoadjuvant
or adjuvant therapy. We demonstrated that INO-1400 or
INO-1401, given with or without INO-9012, demonstrated
an acceptable safety profile in patients with solid tumors.
The majority of related AEs were secondary to administration of the study drug and low grade.
We found that hTERT immunotherapy induced a de
novo cellular immune response or enhanced pre-existing
cellular responses to native hTERT in 96% (88/92) of
patients with various cancer types. It is unclear if we are
rescuing exhausted cells, making new cells, or both. Treatment with INO-1400/INO-1401±INO-9012 drove hTERT-
specific IFN-γ production, generated hTERT-
specific
CD4+ and CD8+T cells expressing the activation marker
CD38 and induced hTERT-specific activated CD8+CTLs
as defined by cells expressing perforin and granzymes. A
post hoc analysis of the dose of hTERT showed similar
cellular immune responses in patients receiving either
the low-dose or high-dose immunotherapy, with no clear
advantage afforded by the higher dose. The addition
of plasmid IL-12 adjuvant elicited higher magnitudes
of cellular responses including IFN-γ production, activated CD4+ and CD8+ T cells, and activated CD8 +CTLs.
Notably, cellular responses in both the ELISpot and LGL
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in the low-dose and high-dose study arms, respectively
(figure 4B, left panel).
The effect of the addition of IL-12 to the immunotherapy regimen was also examined in the LGL assay, for
which the high dose of IL-12 trended toward a numerically
higher mean of activated cells coexpressing lytic proteins
(difference in means of 0.44%), which was not observed
in the low-dose IL-12 and no IL-12 arms (figure 4B, right
panel). Similarly, a trend toward the number of patients
with an increase in the frequency activated CD8 +T
cells with lytic following immunotherapy was observed
with increased amounts of IL-12, that is, 7.4% (2/27) of
patients in the no IL-12 arm, 20% (3/15) in the low-dose
IL-12 arm, and 47.4% (9/19) in the high-dose IL-12 arm
(figure 4B, right panel).
When grouped together by specific tumor type, a range
of responses was observed depending on the tumor
type (figure 4C). Similar mean increases in activated
T cells with lytic potential were observed in the breast
and pancreatic cancer subgroups, 25.0% and 21.1%,
respectively (figure 4C). 33.5% of colorectal and 37.5%
of ovarian patients had an increase in activated CD8 +T
cells with lytic potential; however, the mean frequency of
these cells decreased post treatment. Interestingly, 20%
or more of patients in all subgroups except for those with
lung cancer, had an increase in activated hTERT-specific
CD8 +T cells with lytic potential after immunotherapy.
Patients with lung cancer had a high frequency of these
cells at study entry and they were not boosted following
treatment.
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Figure 5 Association of an immunotherapy induced cytolytic T cell response with survival in a subset of pancreatic cancer
patients. (A) Time (in days) from diagnosis to study day 0, from study day 0 and date of last contact, and survival status for
a subset of pancreatic cancer patients. (B) A representative dot plot of CD8+T cells expressing PD1 and CD69 activation
markers. (C) Activated CD8+T cells expressing granzyme B and perforin in pancreatic patients who were alive or deceased
at the last date of contact. open symbols represent individual patients with a line connecting the preimmunotherapy and
postimmunotherapy magnitudes. The bar extends to the mean. The number and percent of patients in each group that had an
increase, decrease or no change from baseline is displayed below the graph. (D) The change in the frequency of these cytolytic
CD8+T cells (post-pre) in patients based on survival status at the last date of contact. open symbols represent individual
patients, the mean is represented with ‘+’, the box extends from 25th to 75 th percentile, line inside the box is a the median, and
the whiskers extend from the minimum to maximum values. Wilcoxon ranked sum test was used to assess significance. hTERT,
human telomerase reverse transcriptase.
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